Peru Suspends China Vaccine Trials After Detecting “Neuro Problems” Amongst Volunteers
PERU SUSPENDS CHINA VACCINE – Health authorities in Peru temporarily suspended the clinical trials of a coronavirus vaccine from China.
Recently, Peru halted the trials from the Chinese drug powerhouse, Sinopharm. Amid the tests, one of the volunteers was found to have developed neurological problems. As such, the National Institute of Health decided to stop the tests.
According to an article from GMA, chief researcher German Malaga said:
Several days ago we signaled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome
After taking the vaccine, the volunteer had difficulty moving his arms and other problems. Guillain-Barre syndrome is a rare and non-contagious disorder that affects the movement of the arms and legs.
Meanwhile, Peru’s clinical trials of the Chinese vaccine were set to finish this week following the testing of more than 12,000 volunteers. If successful, the government of Peru was supposed to procure up to 20 million doses of the Chinese vaccine to immunize two-thirds of its population.
But, due to the suspension of clinical trials, the Peruvian government won’t know if the trials were a success until mid 2021. However, around 60,000 volunteers across the globe have already taken the Sinopharm vaccine, including volunteers in Argentina, Russia and Saudi Arabia.
Thanks for reading. We aim to provide our readers with the freshest and most in-demand content. Come back next time for the latest news here on Philnews.
Like this article? READ ALSO: Philippines Likely To Get Pfizer Vaccine On These Dates